Cross-platform Q-TOF validation of global exo-metabolomic analysis: Application to human glioblastoma cells treated with the standard PI 3-Kinase inhibitor LY294002
Cross-platform Q-TOF validation of global exo-metabolomic analysis: Application to human glioblastoma cells treated with the standard PI 3-Kinase inhibitor LY294002
复制标题
DOI：
10.1016/j.jchromb.2008.12.001
复制
发表时间：
2009-05-01
影响因子：
3
通讯作者：
Raynaud, F. I.
中科院分区：
文献类型：
--
作者：
Pandher, R.;Ducruix, C.;Raynaud, F. I.
已评估代谢组学方法的重现性，以确定肿瘤细胞代谢物的变化。在Agilent和沃茨LC-Q-TOF仪器上，通过沃茨Acquity T3色谱柱上的反相色谱法（13 min 0.1%甲酸：乙腈梯度）分析组织培养基提取物。通过MarkerLynxTM（沃茨）和分子特征提取器（Agilent）以正离子化和负离子化模式提取特征（m/z，RT）。两种仪器上的特征数量相似，并且十次重复的再现性是相同的。
The reproducibility of a metabolomics method has been assessed to identify changes in tumour cell metabolites. Tissue culture media extracts were analyzed by reverse phase chromatography on a Waters Acquity T3 column with a 13 min 0.1% formic acid: acetonitrile gradient on Agilent and Waters LC-Q-TOF instruments. Features (m/z, RT) were extracted by MarkerLynx (TM) (Waters) and Molecular Feature Extractor (Agilent) in positive and negative ionization modes. The number of features were similar on both instruments and the reproducibility of ten replicates was